Key result
Fondaparinux was superior to LMWH in major orthopaedic surgery, reducing expected DVT (2.3% vs 3.4%) and saving CHF 105 per patient from the health insurer perspective.
Why the study?
Does fondaparinux reduce thromboembolic events and costs compared to LMWH in patients undergoing major orthopaedic surgery?
Does fondaparinux reduce thromboembolic events and costs compared to LMWH in patients undergoing major orthopaedic surgery?
Absolute Event Rate: 2.3% vs 3.4%
Fondaparinux is modeled to be both clinically superior and cost-saving compared to LMWH for thromboembolic prophylaxis in major orthopaedic surgery in Switzerland.
No takes yet. Share an insight, caveat, or question.
May support fondaparinux as cost-effective prophylaxis in major orthopaedic surgery; leaves open prospective confirmation.
Szucs et al. (2005) studied Major orthopaedic surgery. Fondaparinux vs. Low molecular weight heparin (LMWH) was evaluated on Deep vein thrombosis (DVT). Fondaparinux was superior to LMWH in major orthopaedic surgery, reducing expected DVT (2.3% vs 3.4%) and saving CHF 105 per patient from the health insurer perspective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: